Diabetes and Cancer Treatment Becoming Most Lucrative Path for Biotech Industry

[Northerner]

In recent years the FDA has been heavily scrutinized for making the approval process more difficult for drug developers. A ground breaking study released this year by the BIO and BioMedTracker finds that the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is a mere ten percent. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides equity research on Dendreon Corporation /quotes/zigman/83175/quotes/nls/dndn DNDN +7.43% and Biodel, Inc

http://www.marketwatch.com/story/di...tech-industry-2011-10-04?reflink=MW_news_stmp